PharmD Signal

Deep dives, evidence grades, and clinical tools, all in one place.

🧠 Clinical library

Clinical Specialty Index

623 articles indexed across 24 specialties, each reviewed by a licensed pharmacist before publication.

⭐ Featured free samples

Three of our best full deep-analysis reports: hand-picked, free to read in full, no subscription required.

🔓 Free Sample
Nephrology / Renal Pharmacy ConfirmatoryGrade: Moderate

Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD

Finerenone emerges as the safer choice for CKD patients.

Read Free →
🔓 Free Sample
Neurology / Neuropharmacology ConfirmatoryGrade: Low

Tenecteplase Shortens Stroke Treatment and Transfer Times

Tenecteplase speeds up stroke thrombolysis compared to alteplase.

Read Free →
🔓 Free Sample
Rheumatology / Immunology ConfirmatoryGrade: Moderate

EULAR 2025 Streamlines Rheumatoid Arthritis DMARD Management to Nine Recommendations

New EULAR guidelines redefine RA management with DMARDs.

Read Free →
Showing 44 from 1 topic.Sort: Newest | Oldest
Finerenone Outperforms Spironolactone for Cardiorenal Protection in Moderate CKD
🔓 Free Teaser Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Also in Cardiology

Finerenone emerges as the safer choice for CKD patients.

UK Kidney Association Guideline Sets Anticoagulation Framework for AF in Advanced CKD and Dialysis
Guideline Nephrology / Renal Pharmacy Confirmatory Grade: Low

Managing AF in CKD patients is challenging due to bleeding risks.

ICRAKI: Initial Intermittent Dialysis Linked to Higher Mortality Than Continuous Therapy
★ Editor's Pick Analysis Nephrology / Renal Pharmacy Practice-changing Grade: Moderate
Also in Critical Care / ICU

Continuous therapy might reduce mortality in critically ill kidney injury patients.

Dosing Through CRRT: Delivered Clearance, Not eGFR, Should Drive Drug Dosing
Analysis Pharmacokinetics / TDM Confirmatory Grade: Low
Also in Critical Care / ICU, Nephrology

CRRT demands precise drug dosing adjustments in critical care settings.

AUC-Guided Vancomycin in Severe Renal Impairment: Underpowered but Directionally Favorable
Analysis Pharmacokinetics / TDM Hypothesis-generating Grade: Very Low
Also in Infectious Disease / Antimicrobials, Nephrology

Can AUC-guided vancomycin dosing reduce kidney risk in renal impairment?

Oral Obesity Drugs Across CKM Stages: Only Semaglutide Has Outcomes Data
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Also in Cardiology, Nephrology

Oral obesity drugs may redefine CKM syndrome treatment.

Semaglutide Plus Dapagliflozin: Short-Term Gains in Diabetic CKD
Analysis Nephrology / Renal Pharmacy Hypothesis-generating Grade: Very Low
Also in Endocrinology / Diabetes / Obesity

Could combining semaglutide and dapagliflozin benefit diabetic patients with kidney disease?

Sofosbuvir/Daclatasvir Matches Grazoprevir/Elbasvir at 100% SVR12 in Hemodialysis Hepatitis C
Analysis Gastroenterology / Hepatology Hypothesis-generating Grade: Low
Also in Infectious Disease / Antimicrobials, Nephrology

Sofosbuvir/daclatasvir proves effective for hepatitis C in hemodialysis patients.

SGLT2 Inhibitors in Diabetic CKD: Metabolic Wins, Neutral Surrogates
Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Also in Endocrinology / Diabetes / Obesity

SGLT2 inhibitors offer metabolic benefits but risk volume depletion in diabetic CKD.

Pooled semaglutide trials show 16% lower kidney composite risk
Analysis Nephrology / Renal Pharmacy Confirmatory Grade: Moderate
Also in Endocrinology / Diabetes / Obesity

Semaglutide offers potential kidney benefits in cardio-metabolic diseases.

Rituximab Achieves Moderate Renal Response in Difficult Lupus Nephritis
Analysis Rheumatology / Immunology Confirmatory Grade: Low
Also in Nephrology

Rituximab provides moderate renal benefits in hard-to-treat lupus nephritis cases.

First 24 Hours Reveal Massive Medication Burden in Elderly CKD
Analysis Geriatrics / Geriatric Pharmacy Confirmatory Grade: Low
Also in Clinical Practice, Nephrology

Early hospital admission is key for optimizing elderly CKD pharmacotherapy.

Indirect Network Meta-Analysis Ranks Cardiorenal Drugs in Diabetic CKD
Analysis Endocrinology / Diabetes / Obesity Confirmatory Grade: Low
Also in Nephrology, Cardiology

SGLT2 inhibitors show promise for renal outcomes in T2D-CKD.

Renal CDSS Improve Prescribing Processes but Not Proven Outcomes
Analysis Medication Safety Hypothesis-generating Grade: Low
Also in Nephrology

Clinical Decision Support Systems may boost medication safety in CKD patients.

KDIGO 2026 Anemia in CKD Guideline: ESA First, Proactive IV Iron in Hemodialysis
Guideline Nephrology / Renal Pharmacy Practice-changing Grade: Very Low

Updated guidelines prioritize personalized anemia management in chronic kidney disease.